TY - JOUR
T1 - Small bowel adenocarcinoma, version 1.2020
AU - Benson, Al B.
AU - Venook, Alan P.
AU - Al-Hawary, Mahmoud M.
AU - Arain, Mustafa A.
AU - Chen, Yi Jen
AU - Ciombor, Kristen K.
AU - Cohen, Stacey A.
AU - Cooper, Harry S.
AU - Deming, Dustin A.
AU - Garrido-Laguna, Ignacio
AU - Grem, Jean L.
AU - Hoffe, Sarah E.
AU - Hubbard, Joleen
AU - Hunt, Steven
AU - Kamel, Ahmed
AU - Kirilcuk, Natalie
AU - Krishnamurthi, Smitha
AU - Messersmith, Wells A.
AU - Meyerhardt, Jeffrey
AU - Miller, Eric D.
AU - Mulcahy, Mary F.
AU - Steven Nurkin, Md, Ms, Nurkin, Md, Ms
AU - Overman, Michael J.
AU - Parikh, Aparna
AU - Patel, Hitendra
AU - Pedersen, Katrina S.
AU - Saltz, Leonard B.
AU - Schneider, Charles
AU - Shibata, David
AU - Skibber, John M.
AU - Sofocleous, Constantinos T.
AU - Stoffel, Elena M.
AU - Stotsky-Himelfarb, Eden
AU - Willett, Christopher G.
AU - Johnson-Chilla, Alyse
AU - Gregory, Kristina M.
AU - Gurski, Lisa A.
N1 - Publisher Copyright:
© National Comprehensive Cancer Network, Inc. 2019. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Small bowel adenocarcinoma (SBA) is a rare malignancy of the gastrointestinal tract that has increased in incidence across recent years. Often diagnosed at an advanced stage, outcomes for SBA are worse on average than for other related malignancies, including colorectal cancer. Due to the rarity of this disease, few studies have been done to direct optimal treatment, although recent data have shown that SBA responds to treatment differently than colorectal cancer, necessitating a separate approach to treatment. The NCCN Guidelines for Small Bowel Adenocarcinoma were created to establish an evidence-based standard of care for patients with SBA. These guidelines provide recommendations on the workup of suspected SBA, primary treatment options, adjuvant treatment, surveillance, and systemic therapy for metastatic disease. Additionally, principles of imaging and endoscopy, pathologic review, surgery, radiation therapy, and survivorship are described.
AB - Small bowel adenocarcinoma (SBA) is a rare malignancy of the gastrointestinal tract that has increased in incidence across recent years. Often diagnosed at an advanced stage, outcomes for SBA are worse on average than for other related malignancies, including colorectal cancer. Due to the rarity of this disease, few studies have been done to direct optimal treatment, although recent data have shown that SBA responds to treatment differently than colorectal cancer, necessitating a separate approach to treatment. The NCCN Guidelines for Small Bowel Adenocarcinoma were created to establish an evidence-based standard of care for patients with SBA. These guidelines provide recommendations on the workup of suspected SBA, primary treatment options, adjuvant treatment, surveillance, and systemic therapy for metastatic disease. Additionally, principles of imaging and endoscopy, pathologic review, surgery, radiation therapy, and survivorship are described.
KW - Adenocarcinoma/diagnosis
KW - Combined Modality Therapy
KW - Diagnosis, Differential
KW - Humans
KW - Intestinal Neoplasms/diagnosis
KW - Intestine, Small/pathology
KW - Neoplasm Staging
KW - Practice Guidelines as Topic
KW - Risk Factors
KW - Survivorship
KW - Treatment Outcome
KW - Watchful Waiting
UR - https://www.scopus.com/pages/publications/85071741274
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000487242700012&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.6004/jnccn.2019.0043
DO - 10.6004/jnccn.2019.0043
M3 - Review article
C2 - 31487687
SN - 1540-1405
VL - 17
SP - 1109
EP - 1133
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 9
ER -